v3 Template
S

Soligenix, Inc.

Biopharmaceutical Princeton, N.J. ~150 employees
Founded
--
Employees (Est.)
~150
10 leaders known
Total Funding
$36.8M
Funding Rounds
5
Last Funding
2025-09-29

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Products & Services

HyBryte™:Treatment for Cutaneous T-Cell Lymphoma (CTCL), currently in NDA Review stage.
SGX302:Treatment for mild to moderate plaque psoriasis, in development.
RiVax®:Vaccine to prevent ricin poisoning, part of Public Health Solutions, in development.
HyBryte (SGX301) for Cutaneous T-Cell Lymphoma
SGX302 for Mild to Moderate Plaque Psoriasis
SGX942 for Oral Mucositis
SGX945 for Aphthous Ulcers of Behçet’s Disease
RiVax for ricin poisoning prevention
ThermoVax thermostable vaccines

Specialties

Rare disease treatment Orphan drug development Specialized BioTherapeutics Public Health Solutions Cutaneous T-Cell Lymphoma treatment Psoriasis treatment Oral Mucositis treatment Behçet's Disease treatment Ricin poisoning prevention Thermostable vaccine development Biodefense vaccines

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Public Offering
T: -
FT: Public Offering 		A: 7500000
MR: -
FA: 7.5 million
FAN: 7500000 		D: 2025-09-29
FD: 2025-09-29 		-
2 RT: Public Offering
T: -
FT: Public Offering 		A: 7500000
MR: -
FA: 7.5 million
FAN: 7500000 		D: 2025-09-26
FD: 2025-09-26 		1 investors
3 RT: Public Offering
T: -
FT: Public Offering 		A: 4750000
MR: -
FA: $4.75 million
FAN: 4750000 		D: 2024-04-18
FD: 2024-04-18 		-
4 RT: Public Offering
T: -
FT: Public Offering 		A: 8500000
MR: -
FA: $8.5 million
FAN: 8500000 		D: 2023-05-09
FD: 2023-05-09 		1 investors
5 RT: Public Offering
T: -
FT: Public Offering 		A: 8500000
MR: -
FA: 8.5 million
FAN: 8500000 		D: 2023-05-05
FD: 2023-05-05 		-
Public Offering Latest
2025-09-29
$7.5M
Public Offering 2025-09-26
$7.5M
Public Offering 2024-04-18
$4.8M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

C

Christopher J. Schaber

Chairman, President and Chief Executive Officer

G

Gregg A. Lapointe

Board Director

D

Diane L. Parks

Board Director

R

Robert J. Rubin

Board Director

J

Jerome Zeldis

Board Director

C

Christopher J. Schaber

Chairman, President and Chief Executive Officer

View 7 more team members with Pro

Unlock Full Team Directory

Recent News

Soligenix, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biopharmaceutical
Company Size
~150 employees (est.)
Locations
Princeton, N.J.
Princeton, New Jersey

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro